Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: Results from the BIG 02-98 phase III trial

Breast Cancer Research

Volumn 14, Issue 3, 2012, Pages

  Fernández Cuesta, Lynnette ^a   Oakman, Catherine ^b   Falagan Lotsch, Priscila ^a   Smoth, Ke seay ^a   Quinaux, Emmanuel ^c   Buyse, Marc ^c   Dolci, M S ^d   Azambuja, Evandro D ^d   Hainaut, Pierre ^a   Dell'Orto, Patrizia ^e   Larsimont, Denis ^d   Francis, Prudence A ^f,g,h   Crown, John ⁱ   Piccart Gebhart, Martine ^d   Viale, Giuseppe ^e   Leo, Angelo D ^b   Olivier, Magali ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b ISTITUTO TOSCANO TUMORI   (Italy)

^c INTERNATIONAL DRUG DEVELOPMENT INSTITUTE   (Belgium)

^d JULES BORDET INSTITUTE   (Belgium)

^e UNIVERSITY OF MILAN   (Italy)

^f PETER MACCALLUM CANCER CENTRE   (Australia)

^g UNIVERSITY OF NEWCASTLE   (Australia)

^h International Breast Cancer Study Group   (Switzerland)

ⁱ All Ireland Cooperative Oncology Research Group   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; PROTEIN P53;

ADJUVANT THERAPY; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE SEVERITY; EXON; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MISSENSE MUTATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUTANT; PHASE 3 CLINICAL TRIAL; PREDICTIVE VALUE; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SOMATIC MUTATION; TRUNCATING MUTATION; WILD TYPE;

EID: 84861530773     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3179     Document Type: Article

References (47)

1. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997, 88:323-331. 10.1016/S0092-8674(00)81871-1, 9039259.
2. Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell 2009, 137:413-431. 10.1016/j.cell.2009.04.037, 19410540.
3. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, Valentin-Vega YA, Terzian T, Caldwell LC, Strong LC, El-Naggar AK, Lozano G. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 2004, 119:861-872. 10.1016/j.cell.2004.11.006, 15607981.
4. Oren M, Rotter V. Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol 2010, 2:a001107. 10.1101/cshperspect.a001107, 2828285, 20182618.
5. Olivier M, Langerød A, Carrieri P, Bergh J, Klaar S, Eyfjord J, Theillet C, Rodriguez C, Lidereau R, Bièche I, Varley J, Bignon Y, Uhrhammer N, Winqvist R, Jukkola-Vuorinen A, Niederacher D, Kato S, Ishioka C, Hainaut P, Børresen-Dale AL. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res 2006, 12:1157-1167. 10.1158/1078-0432.CCR-05-1029, 16489069.
6. Pharoah PD, Day NE, Caldas C. Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis. Br J Cancer 1999, 80:1968-1973. 10.1038/sj.bjc.6690628, 2363143, 10471047.
7. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, Friend S, Fornace AJ, Kohn KW. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 1997, 57:4285-4300.
8. Wahl A, Donaldson K, Fairchild C, Lee FY, Foster SA, Demers GW, Galloway DA. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med 1996, 2:72-79. 10.1038/nm0196-72, 8564846.
9. Kandioler-Eckersberger D, Ludwig C, Rudas M, Kappel S, Janschek E, Wenzel C, Schlagbauer-Wadl H, Mittlböck M, Gnant M, Steger G, Jakesz R. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin.Cancer Res 2000, 6:50-56.
10. Geisler S, Lonning PE, Aas T, Johnsen H, Fluge O, Haugen DF, Lillehaug JR, Akslen LA, Børresen-Dale AL. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 2001, 61:2505-2512.
11. Di Leo A, Tanner M, Desmedt C, Paesmans M, Cardoso F, Durbecq V, Chan S, Perren T, Aapro M, Sotiriou C, Piccart MJ, Larsimont D, Isola J, . TAX 303 translational study team p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial. Ann Oncol 2007, 18:997-1003. 10.1093/annonc/mdm075, 17369602, TAX 303 translational study team.
12. Glück S, Ross JS, Royce M, McKenna EF, Perou CM, Avisar E, Wu L. TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab. Breast Cancer Res Treat 2012, 132:781-911. 10.1007/s10549-011-1412-7, 21373875.
13. Lara JF, Thor AD, Dressler LG, Broadwater G, Bleiweiss IJ, Edgerton S, Cowan D, Goldstein LJ, Martino S, Ingle JN, Henderson IC, Norton L, Winer EP, Hudis CA, Ellis MJ, Berry DA, Hayes DF, . Cancer and Leukemia Group B p53 Expression in node-positive breast cancer patients: results from the cancer and leukemia group B 9344 trial (159905). Clin Cancer Res 2011, 17:5170-5178. 10.1158/1078-0432.CCR-11-0484, 21693655, Cancer and Leukemia Group B.
14. Bonnefoi H, Piccart M, Bogaerts J, Mauriac L, Fumoleau P, Brain E, Petit T, Rouanet P, Jassem J, Blot E, Zaman K, Cufer T, Lortholary A, Lidbrink E, André S, Litière S, Lago LD, Becette V, Cameron DA, Bergh J, Iggo R, . EORTC 10994/BIG 1-00 Study Investigators TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. Lancet Oncol 2011, 12:527-539. 10.1016/S1470-2045(11)70094-8, 21570352, EORTC 10994/BIG 1-00 Study Investigators.
15. Bonnefoi H, Ducraux A, Movarekhi S, Pelte MF, Bongard S, Lurati E, Iggo R. p53 as a potential predictive factor of response to chemotherapy: feasibility of p53 assessment using a functional test in yeast from trucut biopsies in breast cancer patients. Br J Cancer 2002, 86:750-755. 10.1038/sj.bjc.6600105, 2375302, 11875738.
16. Olivier M, Hainaut P, Borresen-Dale A. Prognostic and predictive value of TP53 mutations in human cancer. 25 years of p53 research 2005, 321-338. The Netherlands: Springer, Hainaut P, Wiman K.
17. Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R, Ishioka C. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci USA 2003, 100:8424-8429. 10.1073/pnas.1431692100, 166245, 12826609.
18. Resnick MA, Inga A. Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity. Proc Natl Acad Sci USA 2003, 100:9934-9939. 10.1073/pnas.1633803100, 187891, 12909720.
19. IARC TP53 Database. , http://www-p53.iarc.fr/
20. Francis P, Crown J, Di Leo A, Buyse M, Balil A, Andersson M, Nordenskjöld B, Lang I, Jakesz R, Vorobiof D, Gutiérrez J, van Hazel G, Dolci S, Jamin S, Bendahmane B, Gelber RD, Goldhirsch A, Castiglione-Gertsch M, Piccart-Gebhart M, . BIG 02-98 Collaborative Group Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. J Natl Cancer Inst 2008, 100:121-133. 10.1093/jnci/djm287, 18182617, BIG 02-98 Collaborative Group.
21. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, Ingle JN, Cooper MR, Hayes DF, Tkaczuk KH, Fleming G, Holland JF, Duggan DB, Carpenter JT, Frei E, Schilsky RL, Wood WC, Muss HB, Norton L. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003, 21:976-983. 10.1200/JCO.2003.02.063, 12637460.
22. Mamounas EP, Bryant J, Lembersky B, Fehrenbacher L, Sedlacek SM, Fisher B, Wickerham DL, Yothers G, Soran A, Wolmark N. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 2005, 23:3686-3696. 10.1200/JCO.2005.10.517, 15897552.
23. Roché H, Fumoleau P, Spielmann M, Canon JL, Delozier T, Serin D, Symann M, Kerbrat P, Soulié P, Eichler F, Viens P, Monnier A, Vindevoghel A, Campone M, Goudier MJ, Bonneterre J, Ferrero JM, Martin AL, Genève J, Asselain B. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial. J Clin Oncol 2006, 24:5664-5671. 10.1200/JCO.2006.07.3916, 17116941.
24. Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, Tomiak E, Al-Tweigeri T, Chap L, Juhos E, Guevin R, Howell A, Fornander T, Hainsworth J, Coleman R, Vinholes J, Modiano M, Pinter T, Tang SC, Colwell B, Prady C, Provencher L, Walde D, Rodriguez-Lescure A, Hugh J, Loret C, Rupin M, Blitz S, Jacobs P, Murawsky M, Riva A, Vogel C, . Breast Cancer International Research Group 001 Investigators Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005, 352:2302-2313. 10.1056/NEJMoa043681, 15930421, Breast Cancer International Research Group 001 Investigators.
25. Martín M, Seguí MA, Antón A, Ruiz A, Ramos M, Adrover E, Aranda I, Rodríguez-Lescure A, Grosse R, Calvo L, Barnadas A, Isla D, Martinez del Prado P, Ruiz Borrego M, Zaluski J, Arcusa A, Muñoz M, López Vega JM, Mel JR, Munarriz B, Llorca C, Jara C, Alba E, Florián J, Li J, López García-Asenjo JA, Sáez A, Rios MJ, Almenar S, Peiró G, Lluch A, . GEICAM 9805 Investigators Adjuvant docetaxel for high-risk, node-negative breast cancer. N Engl J Med 2010, 363:2200-2210. 10.1056/NEJMoa0910320, 21121833, GEICAM 9805 Investigators.
26. Fountzilas G, Skarlos D, Dafni U, Gogas H, Briasoulis E, Pectasides D, Papadimitriou C, Markopoulos C, Polychronis A, Kalofonos HP, Siafaka V, Kosmidis P, Timotheadou E, Tsavdaridis D, Bafaloukos D, Papakostas P, Razis E, Makrantonakis P, Aravantinos G, Christodoulou C, Dimopoulos AM. Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 2005, 16:1762-1771. 10.1093/annonc/mdi366, 16148021.
27. Goldstein LJ, O'Neill A, Sparano JA, Perez EA, Shulman LN, Martino S, Davidson NE. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. J Clin Oncol 2008, 26:4092-4099. 10.1200/JCO.2008.16.7841, 2654376, 18678836.
28. Ellis P, Barrett-Lee P, Johnson L, Cameron D, Wardley A, O'Reilly S, Verrill M, Smith I, Yarnold J, Coleman R, Earl H, Canney P, Twelves C, Poole C, Bloomfield D, Hopwood P, Johnston S, Dowsett M, Bartlett JM, Ellis I, Peckitt C, Hall E, Bliss JM, . TACT Trial Management Group; TACT Trialists Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet 2009, 373:1681-1692. 10.1016/S0140-6736(09)60740-6, 2687939, 19447249, TACT Trial Management Group; TACT Trialists.
29. De Laurentiis M, Cancello G, D'Agostino D, Giuliano M, Giordano A, Montagna E, Lauria R, Forestieri V, Esposito A, Silvestro L, Pennacchio R, Criscitiello C, Montanino A, Limite G, Bianco AR, De Placido S. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 2008, 26:44-53. 10.1200/JCO.2007.11.3787, 18165639.
30. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009, 101:736-750. 10.1093/jnci/djp082, 2684553, 19436038.
31. IARC TP53 Database - Detection of TP53 mutations by direct sequencing.
32. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 2007, 28:622-629. 10.1002/humu.20495, 17311302.
33. Di Leo A, Francis P, Crown JP, de Azambuja E, Quinaux E, Gutierrez J, Nordenskjold B, Andersson M, Margeli Vila M, Piccart-Gebhart M, Jakesz R, Viale G, Olsen S. Overall survival benefit for sequential doxorubicin-docetaxel compared to concomitant doxorubicin and docetaxel in node-positive breast cancer. 8-yr. results of the Breast International Group (BIG) 2-98 phase III adjuvant trial [abstract]. Cancer Res 2009, 69:s601.
34. Bull SB, Ozcelik H, Pinnaduwage D, Blackstein ME, Sutherland DA, Pritchard KI, Tzontcheva AT, Sidlofsky S, Hanna WM, Qizilbash AH, Tweeddale ME, Fine S, McCready DR, Andrulis IL. The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer. J Clin Oncol 2004, 22:86-96.
35. Powell B, Soong R, Iacopetta B, Seshadri R, Smith DR. Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer. Clin Cancer Res 2000, 6:443-451.
36. Langerød A, Zhao H, Borgan T, Nesland JM, Bukholm IR, Ikdahl T, Kåresen R, Børresen-Dale AL, Jeffrey SS. TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Breast Cancer Res 2007, 9:R30. 10.1186/bcr1675, 1929092, 17504517.
37. Turpin E, Bièche I, Bertheau P, Plassa LF, Lerebours F, de Roquancourt A, Olivi M, Espié M, Marty M, Lidereau R, Vidaud M, de Thé H. Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer. Oncogene 2002, 21:7593-7597. 10.1038/sj.onc.1205932, 12386822.
38. de Azambuja E, McCaskill-Stevens W, Francis P, Quinaux E, Crown JP, Vicente M, Giuliani R, Nordenskjöld B, Gutiérez J, Andersson M, Vila MM, Jakesz R, Demol J, Dewar J, Santoro A, Lluch A, Olsen S, Gelber RD, Di Leo A, Piccart-Gebhart M. The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial. Breast Cancer Res Treat 2010, 119:145-153. 10.1007/s10549-009-0512-0, 19731015.
39. Ryu SY, Kim CB, Nam CM, Park JK, Kim KS, Park J, Yoo SY, Cho KS. Is body mass index the prognostic factor in breast cancer?: a meta-analysis. J Korean Med Sci 2001, 16:610-614. 3057588, 11641531.
40. Bertheau P, Turpin E, Rickman DS, Espié M, de Reyniès A, Feugeas JP, Plassa LF, Soliman H, Varna M, de Roquancourt A, Lehmann-Che J, Beuzard Y, Marty M, Misset JL, Janin A, de Thé H. Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. PLoS Med 2007, 4:e90. 10.1371/journal.pmed.0040090, 1831731, 17388661.
41. Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N, Leong CO, Calogrias D, Buraimoh A, Fatima A, Gelman RS, Ryan PD, Tung NM, De Nicolo A, Ganesan S, Miron A, Colin C, Sgroi DC, Ellisen LW, Winer EP, Garber JE. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol 2010, 28:1145-1153. 10.1200/JCO.2009.22.4725, 2834466, 20100965.
42. Pradhan SM, Carey L, Edmiston S, Hylton N, Parrish E, Moore D, Conway K, . I-SPY Clinical Investigators P53 mutation and differential response to neoadjuvant chemotherapy in women with locally advanced breast cancer: results from the I-SPY trial (CALGB 150007/1500012 and ACRIN 6657) [abstract]. J Clin Oncol 2009, 27:s11099. I-SPY Clinical Investigators.
43. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, Liu ET, Bergh J. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 2005, 102:13550-13555. 10.1073/pnas.0506230102, 1197273, 16141321.
44. Troester MA, Herschkowitz JI, Oh DS, He X, Hoadley KA, Barbier CS, Perou CM. Gene expression patterns associated with p53 status in breast cancer. BMC Cancer 2006, 6:276. 10.1186/1471-2407-6-276, 1764759, 17150101.
45. Coutant C, Rouzier R, Qi Y, Lehmann-Che J, Bianchini G, Iwamoto T, Hortobagyi GN, Symmans WF, Uzan S, Andre F, de Thé H, Pusztai L. Distinct p53 gene signatures are needed to predict prognosis and response to chemotherapy in ER-positive and ER-negative breast cancers. Clin Cancer Res 2011, 17:2591-2601. 10.1158/1078-0432.CCR-10-1045, 21248301.
46. He XF, Su J, Zhang Y, Huang X, Liu Y, Ding DP, Wang W, Arparkorn K. Association between the p53 polymorphisms and breast cancer risk: meta-analysis based on case-control study. Breast Cancer Res Treat 2011, 130:517-529. 10.1007/s10549-011-1583-2, 21604156.
47. Bourdon JC, Khoury MP, Diot A, Baker L, Fernandes K, Aoubala M, Quinlan P, Purdie CA, Jordan LB, Prats AC, Lane DP, Thompson AM. p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patients. Breast Cancer Res 2011, 13:R7. 10.1186/bcr2811, 3109573, 21251329.